Urology Times staff

“I think we really hit upon how we work closely together in renal cell cancer—urothelial cancers in particular,” says Joelle Hamilton, MD.

"Men's health, as a sort of separate discipline or a sub discipline within urology, is definitely growing," says Andrew Y. Sun, MD.

“For a lot of settings, a lot of patients, and in a lot of domains within urology, audio visits are equivalent in terms of satisfaction and outcomes to video visits,” says Kara L. Watts, MD.

Roger Li, MD, highlights 4 studies in bladder cancer being presented at the 2023 American Urological Association Annual Meeting.

Physicians are now using the AI-powered Unfold AI platform to work with patients on treatment selection and establishing an optimal overall management plan.

"Not only do we lose patients and we lose this opportunity to actually take good care of them, but it actually undermines their trust in us as a profession," says A. Lenore Ackerman, MD, PhD.

“It's pretty apparent that if physicians are not going to be reimbursed properly for telehealth, they're not going to use utilize it,” says Lisa J. Finkelstein, DO, FACOS.

“I think being savvy about how you deal with BCG supply on the administrative side is important,” says Suzanne B. Merrill, MD, FACS.

"At the end [of my talk], I really wanted to focus on how Specialty Networks could partner with us," says Jannah H. Thompson, MD, FPMRS.

This marks the first worldwide approval for the niraparib/abiraterone dual-action tablet.

“Allowing the waiver to continue indefinitely would be a tremendous win for telehealth for both sides, the patients and the health care providers,” says Kara L. Watts, MD.

Scott T. Tagawa, MD, discusses trials exploring 177Lu-PSMA-617 in settings earlier than it’s FDA-approved indication for patients with heavily pretreated metastatic castration-resistant prostate cancer.

Melissa A. Laudano, MD, highlights 3 studies in overactive bladder/incontinence being presented at the 2023 American Urological Association Annual Meeting.

Helen L. Bernie, DO, MPH, highlights 4 studies in sexual dysfunction being presented at the 2023 American Urological Association Annual Meeting.

“In terms of next steps, we are collaborating with other institutions…to see how our model performs in their patient populations,” says Eric Li, MD.

Michael S. Cookson, MD, MMHC, highlights 5 studies in prostate cancer being presented at the 2023 American Urological Association Annual Meeting.

"In the periods where BCG utilization dropped, we saw a concomitant increase in mitomycin C," says Brian Chun, MD.

“He’s had just such a huge impact for me as a role model, a teacher, a wonderful support system, just such a kind-hearted person,” says Stacy Loeb, MD, MSc, PhD (hon).

“Waiting for others to fix health care is not a good strategy. Instead, be determined to begin your journey to your mountaintop of joy and fulfillment,” says Scott A. MacDiarmid, MD, FRCPSC.

"Even just the process of getting that β3 agonist is going to cost them time and energy and effort that can be quite frustrating and take a lot out of you," says A. Lenore Ackerman, MD, PhD.

“We were actually quite pleased with how well our model performed, particularly in the independent cohort that was separate from our training cohort,” says Eric Li, MD.

"About 30% of women screened positive, but of course when we looked at [the data] stratified by age, about 50% of women 65 years and older had a positive screen," says Steven R. Fisher, PhD, PT, GCS.

"We are optimistic about this study, because it has the potential not just only for vesicovaginal fistula treatment, but it can be also used in the treatment of burns for other fistula types," says Ilaha Isali, MD.

Chandler Park, MD, discusses lessons from the ARASENS and TITAN trials on the use of triplet vs doublet therapy in patients with metastatic hormone-sensitive prostate cancer.

“The first thing I'd say is that we know these devices are safe,” says Colin Goudelocke, MD.

"Our second line [for overactive bladder] is our medications. These often can be very effective for patients, but we find that they can be also extremely limited by adverse events that are associated with those medications," says A. Lenore Ackerman, MD, PhD.

The safety and efficacy of the Vivally System were established in the FREEOAB study, a prospective multi-center clinical trial that included 96 patients with overactive bladder.

“I think clinicians can really take away that we have more work to be done in this space of evaluating patients with microhematuria, specifically when it comes to looking at assessments of upper tract urothelial carcinoma or renal cell carcinoma,” says Jacob Taylor, MD, MPH.

“We want to minimize our negative biopsies and diagnosis of grade group 1 cancers,” says Rashid Siddiqui, MD.